SightGlass Vision Launches “Control the Contrast” Professional Education Campaign for Myopia Control

Focus on Contrast Management Aims to Raise Awareness, Educate, and Inspire Action to Slow Myopia Progression in Children

DALLAS, April 20, 2026—SightGlass Vision today announced the launch of its new global professional education campaign, “Control the Contrast,” to create greater understanding among eye care professionals about the power of contrast management for myopia control. The initiative centers around DOT™ spectacle lenses, which have been shown to slow average myopia progression by up to 75% after 12 months of wear across diverse populations.^1,2*

Children are spending more time indoors, studying, reading, and playing in modern, artificial environments, which may be linked to accelerated myopia progression.^3-7 DOT lenses mimic more natural contrast by integrating thousands of elements that softly scatter light before it hits the retina.⁸ The spectacle lenses have made their commercial debut in Canada, China, Israel, Spain, and the U.K., with over 1.5 million children having already worn them.^9†

Eye care professionals are invited to explore the “Control the Contrast” website at sightglassvision.com/controlthecontrast. The website houses a range of dynamic content, including details on how the contrast levels in various environments may lead to very different levels of eye growth, as well as downloadable DOT lens materials.¹⁰

“More children are developing myopia at a younger age, making it even more crucial for eye care professionals to be aware of all the options at their disposal for early intervention,” said Andrew Sedgwick, CEO of SightGlass Vision.¹¹ “By building awareness and understanding of the science behind contrast management and DOT lenses’ unique approach to controlling myopia, we hope more eye care professionals will take action.”

“What convinced me about DOT lenses was seeing the results within my own practice,” said Kylvin Ho, OD, of C U Vision Optometrists in Vancouver. “We’ve seen a high success rate, especially in our younger patients, with many showing slowed progression and stable axial length over time. The lenses are easy to fit, low risk, and families are genuinely happy with them, which makes a huge difference. I encourage more practitioners to take the time to understand the role of contrast in myopia management and see how straightforward it is to incorporate DOT lenses into their practice.”

Founded in 2016, SightGlass Vision now operates as a joint venture of CooperVision, Inc. and Essilor International. For more information, visit SightGlassVision.com.

###

About SightGlass Vision

SightGlass Vision™ develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™ is based on landmark discoveries surrounding myopia progression. DOT™ spectacle lenses using its patent-protected approach incorporate thousands of light-scattering elements designed to mimic more natural contrast on the retina. DOT™ lenses provide myopia control through contrast management and have proven results from Gold-standard clinical trials in North America and China. Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International to accelerate commercialization opportunities and expand the myopia management category worldwide.

^* Patient population aged 6–10 years (CYPRESS) and 6–13 years (CATHAY). Prescribed DOT lens wear time was 10 hours per day.

^† SightGlass Vision™ DOT™ spectacle lenses are not available for sale in the United States.

 

Media Contact
Carson Daniels, Senior Counselor
McDougall Communications for SightGlass Vision
+1-315-427-6394 or [email protected]